比较奥沙拉嗪和柳氮磺胺吡啶用于溃疡性结肠炎维持治疗的对照试验。
Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis.
作者信息
Ireland A, Mason C H, Jewell D P
机构信息
Gastroenterology Unit, Radcliffe Infirmary, Oxford.
出版信息
Gut. 1988 Jun;29(6):835-7. doi: 10.1136/gut.29.6.835.
Abstract
One hundred and sixty four patients with ulcerative colitis in remission were entered into a double blind, double dummy trial comparing olsalazine 500 mg bd and sulphasalazine 1 g bd. Clinical examination, sigmoidoscopy and rectal biopsy were performed at 0, three, and six months. Sixteen of 82 (19.5%) patients relapsed on olsalazine and 10/82 (12.2%) relapsed on sulphasalazine. The difference was not statistically significant (p = 0.1632). Adverse events were minor and were similar in both groups. No haematological or biochemical abnormalities were detected. Thus, olsalazine is as effective as sulphasalazine for preventing a relapse of ulcerative colitis.
摘要
164例溃疡性结肠炎缓解期患者进入一项双盲、双模拟试验，比较500毫克柳氮磺吡啶每日两次和柳氮磺胺吡啶1克每日两次的疗效。在0、3和6个月时进行临床检查、乙状结肠镜检查和直肠活检。82例服用柳氮磺吡啶的患者中有16例（19.5%）复发，82例服用柳氮磺胺吡啶的患者中有10例（12.2%）复发。差异无统计学意义（p = 0.1632）。不良事件轻微，两组相似。未检测到血液学或生化异常。因此，柳氮磺吡啶在预防溃疡性结肠炎复发方面与柳氮磺胺吡啶同样有效。
相似文献
1
Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis.比较奥沙拉嗪和柳氮磺胺吡啶用于溃疡性结肠炎维持治疗的对照试验。
Gut. 1988 Jun;29(6):835-7. doi: 10.1136/gut.29.6.835.
2
Controlled trial comparing olsalazine and sulphasalazine for maintenance treatment of ulcerative colitis.奥沙拉嗪与柳氮磺胺吡啶用于溃疡性结肠炎维持治疗的对照试验。
Scand J Gastroenterol Suppl. 1988;148:45-7. doi: 10.3109/00365528809101547.
3
Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group.奥沙拉嗪与柳氮磺胺吡啶在溃疡性结肠炎维持治疗12个月期间的预防效果。丹麦奥沙拉嗪研究小组。
Gut. 1992 Feb;33(2):252-5. doi: 10.1136/gut.33.2.252.
4
Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized multicenter study. The Ulcerative Colitis Multicenter Study Group.柳氮磺胺吡啶和奥沙拉嗪对溃疡性结肠炎缓解期患者的预防复发作用及安全性：一项前瞻性、双盲、随机多中心研究。溃疡性结肠炎多中心研究组。
Am J Gastroenterol. 1992 Apr;87(4):438-42.
5
Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis.奥沙拉嗪与柳氮磺胺吡啶作为溃疡性结肠炎维持治疗的双盲剂量探索性研究。
Eur J Gastroenterol Hepatol. 1995 May;7(5):391-6.
6
Double-blind comparison of olsalazine and sulphasalazine in active ulcerative colitis.奥沙拉嗪与柳氮磺胺吡啶治疗活动期溃疡性结肠炎的双盲对照研究
Scand J Gastroenterol Suppl. 1988;148:40-4. doi: 10.3109/00365528809101546.
7
Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study.奥沙拉嗪与柳氮磺胺吡啶预防溃疡性结肠炎复发的多中心研究
Am J Gastroenterol. 1995 Mar;90(3):381-7.
8
Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study.奥沙拉嗪或柳氮磺胺吡啶用于溃疡性结肠炎初发发作？一项双盲研究。
Gut. 1989 May;30(5):675-9. doi: 10.1136/gut.30.5.675.
9
Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects.用奥沙拉嗪和柳氮磺胺吡啶治疗溃疡性结肠炎：疗效与副作用
Scand J Gastroenterol Suppl. 1988;148:70-5. doi: 10.3109/00365528809101553.
引用本文的文献
1
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.口服5-氨基水杨酸用于维持溃疡性结肠炎缓解
Cochrane Database Syst Rev. 2020 Aug 28;8(8):CD000544. doi: 10.1002/14651858.CD000544.pub5.
2
AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis.美国胃肠病学会关于轻至中度溃疡性结肠炎管理的临床实践指南。
Gastroenterology. 2019 Feb;156(3):748-764. doi: 10.1053/j.gastro.2018.12.009. Epub 2018 Dec 18.
3
AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.AGA 技术评论：轻度至中度溃疡性结肠炎的治疗。
Gastroenterology. 2019 Feb;156(3):769-808.e29. doi: 10.1053/j.gastro.2018.12.008. Epub 2018 Dec 18.
4
Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.比较药物治疗轻中度溃疡性结肠炎的疗效和耐受性：系统评价和网络荟萃分析。
Lancet Gastroenterol Hepatol. 2018 Nov;3(11):742-753. doi: 10.1016/S2468-1253(18)30231-0. Epub 2018 Aug 17.
5
Histologic scoring indices for evaluation of disease activity in ulcerative colitis.用于评估溃疡性结肠炎疾病活动度的组织学评分指标。
Cochrane Database Syst Rev. 2017 May 25;5(5):CD011256. doi: 10.1002/14651858.CD011256.pub2.
6
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.口服5-氨基水杨酸用于维持溃疡性结肠炎的缓解。
Cochrane Database Syst Rev. 2016 May 9;2016(5):CD000544. doi: 10.1002/14651858.CD000544.pub4.
7
A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis.一项关于柳氮磺胺吡啶与5-氨基水杨酸酯在诱导溃疡性结肠炎患者病情改善及维持缓解方面疗效对比的荟萃分析。
Dig Dis Sci. 2009 Jun;54(6):1157-70. doi: 10.1007/s10620-008-0481-x. Epub 2008 Sep 4.
8
Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes.改善溃疡性结肠炎中氨基水杨酸盐的给药方式：对患者预后的影响。
Drugs. 2008;68(8):1089-103. doi: 10.2165/00003495-200868080-00006.
9
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.每日一次或两次MMX美沙拉嗪维持溃疡性结肠炎缓解的随机试验。
Gut. 2008 Jul;57(7):893-902. doi: 10.1136/gut.2007.138248. Epub 2008 Feb 13.
10
How important is onset of action in ulcerative colitis therapy?在溃疡性结肠炎治疗中，起效时间有多重要？
Drugs. 2005;65(15):2069-83. doi: 10.2165/00003495-200565150-00001.
本文引用的文献
1
Biopsy studies in ulcerative colitis.溃疡性结肠炎的活检研究。
Br Med J. 1956 Jun 9;1(4979):1315-8. doi: 10.1136/bmj.1.4979.1315.
2
Cortisone in ulcerative colitis; final report on a therapeutic trial.可的松治疗溃疡性结肠炎；一项治疗试验的最终报告
Br Med J. 1955 Oct 29;2(4947):1041-8. doi: 10.1136/bmj.2.4947.1041.
3
Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.偶氮双水杨酸二钠在健康志愿者体内的分布与代谢，偶氮双水杨酸二钠是一种潜在的溃疡性结肠炎治疗药物。
Gut. 1982 Dec;23(12):1081-7. doi: 10.1136/gut.23.12.1081.
4
Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis.通过对健康志愿者和溃疡性结肠炎患者进行体内透析测定结肠偶氮水杨酸代谢情况。
Gastroenterology. 1984 Jun;86(6):1496-500.
5
Sulfasalazine. Adverse effects and desensitization.柳氮磺胺吡啶。不良反应与脱敏疗法。
Dig Dis Sci. 1983 Sep;28(9):833-42. doi: 10.1007/BF01296907.
6
A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).柳氮磺胺吡啶（水杨酸偶氮磺胺吡啶）对溃疡性结肠炎进行长期维持治疗的对照治疗试验。
Gut. 1973 Dec;14(12):923-6. doi: 10.1136/gut.14.12.923.
7
Olsalazine in active ulcerative colitis.奥沙拉嗪治疗活动期溃疡性结肠炎。
Br Med J (Clin Res Ed). 1985 Nov 16;291(6506):1373-5. doi: 10.1136/bmj.291.6506.1373.
8
Effects of olsalazine in the jejunum of the rat.奥沙拉嗪对大鼠空肠的作用。
Gut. 1987 Mar;28(3):346-52. doi: 10.1136/gut.28.3.346.
9
Effect of azodisal sodium and sulphasalazine on ileostomy output of fluid and PGE2 and PGF2 alpha in subjects with a permanent ileostomy.偶氮双水杨酸二钠和柳氮磺胺吡啶对永久性回肠造口术患者回肠造口液输出量及前列腺素E2和前列腺素F2α的影响。
Gut. 1986 Nov;27(11):1306-11. doi: 10.1136/gut.27.11.1306.
10
Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties.偶氮双水杨酸二钠治疗溃疡性结肠炎。耐受性及预防复发特性的研究。
Gastroenterology. 1986 Apr;90(4):1024-30. doi: 10.1016/0016-5085(86)90882-6.
Zotero 插件